Renaissance Technologies - ENANTA PHARMACEUTICALS INC ownership

ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 181 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of ENANTA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$5,117
-49.8%
458,100
-3.8%
0.01%
-40.0%
Q2 2023$10,193
-41.0%
476,300
+11.4%
0.02%
-34.8%
Q1 2023$17,287
-21.5%
427,464
-9.7%
0.02%
-23.3%
Q4 2022$22,013
-99.9%
473,200
+1.1%
0.03%
-11.8%
Q3 2022$24,275,000
-5.4%
468,000
-13.8%
0.03%
+13.3%
Q2 2022$25,658,000
-40.6%
542,800
-10.6%
0.03%
-41.2%
Q1 2022$43,213,000
-19.1%
607,100
-15.0%
0.05%
-22.7%
Q4 2021$53,423,000
+24.3%
714,400
-5.6%
0.07%
+17.9%
Q3 2021$42,982,000
+22.4%
756,585
-5.2%
0.06%
+27.3%
Q2 2021$35,108,000
-20.9%
797,728
-11.4%
0.04%
-20.0%
Q1 2021$44,398,000
+2.0%
900,200
-12.9%
0.06%
+17.0%
Q4 2020$43,527,000
-7.6%
1,033,900
+0.5%
0.05%0.0%
Q3 2020$47,108,000
-0.5%
1,029,000
+9.1%
0.05%
+14.6%
Q2 2020$47,343,000
+4.5%
942,900
+7.1%
0.04%
-6.8%
Q1 2020$45,289,000
+0.2%
880,600
+20.4%
0.04%
+25.7%
Q4 2019$45,198,000
+13.5%
731,600
+10.4%
0.04%
+2.9%
Q3 2019$39,827,000
-14.2%
662,900
+20.5%
0.03%
-17.1%
Q2 2019$46,434,000
-24.7%
550,300
-14.7%
0.04%
-26.8%
Q1 2019$61,659,000
+9.2%
645,505
-19.0%
0.06%
-9.7%
Q4 2018$56,466,000
-22.1%
797,200
-6.0%
0.06%
-17.3%
Q3 2018$72,504,000
-57.4%
848,400
-50.8%
0.08%
-19.4%
Q2 2018$170,179,000
+148.9%
1,723,400
+104.0%
0.09%
+24.0%
Q1 2018$68,361,000
+51.0%
844,900
+9.5%
0.08%
+50.0%
Q4 2017$45,277,000
+42.0%
771,600
+13.3%
0.05%
+31.6%
Q3 2017$31,875,000
+42.8%
681,100
+9.8%
0.04%
+35.7%
Q2 2017$22,326,000
+27.7%
620,500
+9.3%
0.03%
+16.7%
Q1 2017$17,485,000
-9.2%
567,693
-1.2%
0.02%
-20.0%
Q4 2016$19,255,000
+3.2%
574,771
-18.1%
0.03%
-9.1%
Q3 2016$18,664,000
+456.1%
701,400
+360.8%
0.03%
+450.0%
Q2 2016$3,356,000
+105.5%
152,200
+173.7%
0.01%
+100.0%
Q1 2016$1,633,000
-50.4%
55,600
-33.2%
0.00%
-66.7%
Q3 2014$3,295,000
+40.1%
83,277
+52.5%
0.01%
+80.0%
Q2 2014$2,352,000
+34.1%
54,600
-15.1%
0.01%
+25.0%
Q4 2013$1,754,00064,3000.00%
Other shareholders
ENANTA PHARMACEUTICALS INC shareholders Q2 2020
NameSharesValueWeighting ↓
Krensavage Asset Management, LLC 735,103$8,2113.02%
BRAIDWELL LP 1,038,310$11,597,9230.37%
ARMISTICE CAPITAL, LLC 2,100,000$23,457,0000.36%
FARALLON CAPITAL MANAGEMENT LLC 1,875,000$20,943,7500.10%
PDT Partners, LLC 67,318$751,9420.10%
Virtus ETF Advisers LLC 12,784$142,7970.09%
Portland Global Advisors LLC 34,175$3820.06%
XTX Topco Ltd 27,222$304,0700.05%
Trexquant Investment LP 132,561$1,480,7060.04%
SHERBROOKE PARK ADVISERS LLC 10,100$112,8170.04%
View complete list of ENANTA PHARMACEUTICALS INC shareholders